NASDAQ:XLO Xilio Therapeutics (XLO) Stock Price, News & Analysis $8.31 +0.16 (+1.96%) Closing price 03:59 PM EasternExtended Trading$8.24 -0.07 (-0.78%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Xilio Therapeutics Stock (NASDAQ:XLO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xilio Therapeutics alerts:Sign Up Key Stats Today's Range$8.08▼$8.3150-Day Range$7.71▼$8.8152-Week Range$6.47▼$12.74Volume8,269 shsAverage Volume41,589 shsMarket Capitalization$54.68 millionP/E RatioN/ADividend YieldN/APrice Target$28.00Consensus RatingModerate Buy Company Overview Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity. The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands. These candidates are designed to selectively accumulate in tumor tissues and activate local innate and adaptive immunity. Xilio has advanced multiple assets into early‐phase clinical studies, evaluating safety, pharmacokinetics and preliminary signals of anti‐tumor activity across various solid tumor types. The pipeline also includes additional preclinical programs that apply the same targeting and activation principles to other cytokine payloads. Founded in 2018 and headquartered in Cambridge, Massachusetts, Xilio Therapeutics has assembled a management team with deep experience in oncology drug development and biologics engineering. The company conducts its clinical trials primarily in the United States and Europe and collaborates with academic and industry partners to accelerate the translation of its pipeline candidates into potential cancer therapies. Xilio remains committed to advancing its modular cytokine platform to address unmet needs in immuno‐oncology.AI Generated. May Contain Errors. Read More Xilio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreXLO MarketRank™: Xilio Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 479th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingXilio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.Upside PotentialXilio Therapeutics has a consensus price target of $28.00, representing about 236.9% upside from its current price of $8.31.Amount of Analyst CoverageXilio Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Xilio Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xilio Therapeutics are expected to grow in the coming year, from ($2.39) to $0.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xilio Therapeutics is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xilio Therapeutics is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXilio Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Xilio Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.09% of the float of Xilio Therapeutics has been sold short.Short Interest Ratio / Days to CoverXilio Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xilio Therapeutics has recently increased by 5.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXilio Therapeutics does not currently pay a dividend.Dividend GrowthXilio Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News SentimentN/A News SentimentXilio Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Xilio Therapeutics this week, compared to 1 article on an average week. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.45% of the stock of Xilio Therapeutics is held by insiders.Percentage Held by Institutions54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xilio Therapeutics' insider trading history. Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XLO Stock News HeadlinesXilio Therapeutics IncJune 2 at 7:33 AM | edition.cnn.comXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesMay 12, 2026 | globenewswire.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.June 4 at 1:00 AM | Brownstone Research (Ad)Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 | globenewswire.comXilio Therapeutics (XLO) price target decreased by 28.57% to 20.40April 28, 2026 | msn.comXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2April 17, 2026 | globenewswire.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsApril 16, 2026 | markets.businessinsider.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.April 16, 2026 | globenewswire.comSee More Headlines XLO Stock Analysis - Frequently Asked Questions How have XLO shares performed this year? Xilio Therapeutics' stock was trading at $8.9628 on January 1st, 2026. Since then, XLO shares have decreased by 7.3% and is now trading at $8.31. How were Xilio Therapeutics' earnings last quarter? Xilio Therapeutics, Inc. (NASDAQ:XLO) released its earnings results on Tuesday, May, 12th. The company reported ($0.58) EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.08. The firm had revenue of $12.65 million for the quarter, compared to analysts' expectations of $8.52 million. Xilio Therapeutics had a negative trailing twelve-month return on equity of 151.42% and a negative net margin of 58.52%. When did Xilio Therapeutics' stock split? Shares of Xilio Therapeutics reverse split before market open on Friday, March 13th 2026.The 1-14 reverse split was announced on Thursday, March 12th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 12th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Xilio Therapeutics IPO? Xilio Therapeutics (XLO) raised $125 million in an initial public offering on Wednesday, October 20th 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share. How do I buy shares of Xilio Therapeutics? Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xilio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include PayPal (PYPL), Achilles Therapeutics (ACHL), JPMorgan Chase & Co. (JPM), AT&T (T), United Microelectronics (UMC), Adverum Biotechnologies (ADVM) and Atai Beckley (ATAI). Company Calendar Last Earnings5/12/2026Today6/04/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (12m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 XLO's financial health is in the Yellow zone, according to TradeSmith. XLO has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XLO CIK1840233 Webwww.xiliotx.com Phone857-524-2466FaxN/AEmployees70Year Founded2015Price Target and Rating Average Price Target for Xilio Therapeutics$28.00 High Price Target$28.00 Low Price Target$28.00 Potential Upside/Downside+236.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($3.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.04 million Net Margins-58.52% Pretax Margin-58.52% Return on Equity-151.42% Return on Assets-27.61% Debt Debt-to-Equity RatioN/A Current Ratio3.59 Quick Ratio3.59 Sales & Book Value Annual Sales$43.77 million Price / Sales1.25 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book1.14Miscellaneous Outstanding Shares6,580,000Free Float6,085,000Market Cap$54.68 million OptionableNot Optionable Beta-0.12 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:XLO) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersDo NOT Buy SpaceX – Do This InsteadSpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...Stansberry Research | SponsoredBOXABL Expected to Trade as $BXBLBOXABL, known for its factory-built, foldable Casita homes that unfold on-site in under an hour, has announced...BOXABL | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
